Key result
Dynamic second-generation antipsychotic dosing patterns highlight the need for fixed-dose comparative studies.
Why the study?
Dosing patterns with second-generation antipsychotic medications are dynamic and vary from initial regulatory guidelines, necessitating updated understanding and fixed-dose studies.
This review highlights the dynamic nature of SGA dosing patterns and emphasizes the need for fixed-dose studies and careful dosing considerations in comparative research.
SGA dosing merits primary clinical consideration; leaves open optimal fixed-dose regimens pending dedicated trials.
Dosing patterns with second-generation antipsychotic medications (SGAs) are dynamic, with some SGAs surpassing current recommendations while others are declining in dose since their initial regulatory guidelines. Pertinent recent studies and available pharmacoepidemiologic reports, information, and expert consenses are reviewed herein to illuminate current thinking on the topic of dosing with SGAs. There is a need for fixed-dose studies of each SGA. Additionally, dosing should be a primary consideration when designing and subsequently interpreting comparative studies between SGAs.
No takes yet. Share an insight, caveat, or question.
P.F. Buckley (2004) reported a review. Second-generation antipsychotic medications (SGAs) was evaluated. Dosing patterns with second-generation antipsychotic medications are dynamic, highlighting the need for fixed-dose studies and careful consideration of dosing in comparative studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: